Trial Profile

proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotorasib (Primary)
Indications Liver metastases; Non-small cell lung cancer
Focus Pharmacokinetics
Acronyms START-TKI

Most Recent Events

24 Oct 2023 Results (At data cut off: 28 April 2023, n=90) assessing potential association between the time interval between prior IO and sotorasib and the incidence of severe hepatotoxicity, presented at the 48th European Society for Medical Oncology Congress.
17 May 2023 New trial record
19 Apr 2023 Results(n=35) assessing Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com